Korean J Perinatol.
2011 Mar;22(1):52-56.
Saccharomyces cereviciae Sepsis after Treatment of Saccharomyces boulardii Probiotics in Premature Infants
- Affiliations
-
- 1Department of Pediatrics, Keimyung University School of Medicine, Daegu, Korea. cskim@dsmc.or.kr
Abstract
- Saccharomyces boulardii is a probiotic compound which is widely used for prevention and treatment of various diarrhea disorders and enhancement of gastrointestinal functions. Although clinical data have suggested that this agent is safe and effective, it can rarely cause systemic infections in immune compromised hosts. It is difficult to differentiate between the strain of S. boulardii and Saccharomyces cereviciae in clinical specimens with routine diagnostic methods. I experienced two cases of S. cereviciae fungemia after treatment of S. boulardii probiotics in premature infants with recurrent feeding intolerance. S. boulardii agents may cause systemic infections in premature infants; therefore the attention must be paid prior to the use of it.